Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia

NCT02634346 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02634346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
June 7, 2017
Enrollment
403 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia